Life science company BioDuro LLC revealed on Friday the election of Kent Payne, PhD as president of its CMC Global Solutions business.
Currently, Dr Payne is a board member for Goodwin Biotechnologies, a biological contract manufacturer, as well as board advisor for Vitruvias Therapeutics, a specialty generic pharmaceutical business.
Most recently, Dr Payne was employed as chief executive officer at Socorro Pharmaceuticals, a generic pharmaceutical company.
Previously, Dr Payne served as president Americas at Qualicaps Inc, principal consultant and partner at CoreFactor LLC and vice president/general manager at Catalent Pharma Solutions Inc. He has also held progressive leadership roles at Novartis, Monsanto and G.D. Searle.
Earlier, Dr Payne has held board and advisory roles at Life Science Institute Inc, a wholly-owned subsidiary of Mitsubishi Chemical Holdings, Technophar Inc, Qualicaps Inc and PDS Biotechnology (PDSB).
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream